A Complete Checklist for Preparing Cell Therapies for Commercialisation

Cell therapies are changing the way serious diseases are treated. Unlike traditional medicines, these therapies involve living cells that require careful handling from collection to delivery. That makes commercialisation far more demanding than simply increasing production.

A successful launch depends on much more than scientific progress. Companies need reliable logistics, scalable manufacturing, strict quality systems, and a practical market strategy. Missing any of these areas can slow approvals, increase costs, or affect product quality.

Working with an experienced cell and gene therapy CDMO can help companies build the right foundation early. This checklist covers the main areas that should be in place before bringing a cell therapy to the commercial market.

1. Build a Reliable Supply Chain and Logistics Network

The supply chain is one of the most important parts of cell therapy commercialisation. Since many therapies use a patient's own cells, every sample must remain correctly identified throughout the process.

Establish Chain of Identity and Chain of Custody

Every collected sample should stay linked to the correct patient from collection through manufacturing and final delivery. Companies also need complete records showing every person who handled the product during each stage.

Strong Chain of Identity and Chain of Custody systems reduce errors and provide the documentation regulators expect during inspections.

Create a Stable Cold Chain

Cell therapies remain highly sensitive to temperature changes. Even small variations can affect cell quality and reduce treatment effectiveness.

A commercial supply chain should include:

• Cryogenic shipping using liquid nitrogen

• Validated storage conditions

• Continuous temperature monitoring

• Emergency transport procedures

• Qualified logistics partners

Every shipment should move safely between hospitals, manufacturing facilities, and treatment centres without compromising product integrity.

Train Collection Sites

Commercial success begins at the hospital. Healthcare teams must understand how to collect, package, label, and ship patient material correctly.

Clear standard operating procedures and regular training help reduce handling mistakes before manufacturing even begins.

2. Prepare Manufacturing for Commercial Scale

Processes that work well in research laboratories often become difficult to manage during commercial production. Companies need manufacturing systems that maintain consistent quality while supporting larger patient volumes.

Many organisations rely on cell therapy manufacturing services to transition from clinical production to commercial readiness without disrupting development timelines.

Move Toward Automated Manufacturing

Manual production introduces more opportunities for contamination and process variation.

Closed, automated manufacturing platforms improve consistency by reducing direct operator involvement. Automation also helps facilities produce more batches while maintaining quality standards.

Control Critical Raw Materials

Every ingredient used during manufacturing affects the final product. Growth media, enzymes, cytokines, and other materials should undergo careful evaluation before commercial production begins. 

Suppliers should meet strict quality standards and provide consistent materials across every manufacturing campaign. Maintaining raw material consistency reduces batch-to-batch variation and supports long-term product reliability.

Build a Realistic Cost Model

Autologous therapies require individualised manufacturing for every patient. This creates higher production costs than conventional pharmaceutical products.

Companies should evaluate:

• Manufacturing expenses

• Labor requirements

• Raw material costs

• Logistics expenses

• Facility utilisation

• Future production capacity

Financial planning helps maintain sustainable pricing while supporting future expansion.

3. Build Strong Quality and Regulatory Systems

Commercial manufacturing requires continuous quality oversight. Regulatory agencies expect companies to demonstrate that every product meets predefined standards before reaching patients. Strong documentation also supports smoother inspections and regulatory submissions.

Validate Product Quality

Testing methods should consistently measure:

• Identity

• Purity

• Potency

• Sterility

• Safety

Validated analytical methods help confirm that every manufactured batch performs as expected before release.

Work with Regulatory Authorities Early

Regulatory planning should begin long before commercial launch. Companies should maintain regular communication with agencies such as the FDA and the European Medicines Agency throughout development. 

Early discussions reduce uncertainty and help manufacturing processes align with regulatory expectations. Preparing complete manufacturing documentation also supports faster review during submission.

Maintain Complete Manufacturing Records

Every production step should be documented carefully. Detailed batch records allow manufacturers to investigate deviations, review historical data, and identify root causes whenever problems occur. Retaining reference samples also supports future investigations if necessary.

Many organisations choose end-to-end CDMO services because integrated development, manufacturing, quality management, and regulatory support simplify documentation across the entire product lifecycle.

4. Prepare for Market Access and Commercial Success

Regulatory approval marks an important milestone, but commercialisation continues well beyond product approval. Companies also need strategies for reimbursement, physician education, and patient access.

Demonstrate Long-Term Value

Traditional medicines often require continuous treatment. Cell therapies frequently involve a single treatment with long-lasting clinical benefit.

Healthcare providers and insurance organisations want evidence that these therapies justify their higher upfront costs. Long-term clinical outcomes, health economics studies, and patient follow-up data all support reimbursement discussions.

Educate Commercial Teams

Sales and medical teams should understand every aspect of the therapy.

Training should cover:

• Manufacturing process

• Clinical evidence

• Treatment pathway

• Patient eligibility

• Product handling requirements

• Safety information

Well-prepared teams communicate more effectively with physicians and healthcare providers.

Develop Payment and Patient Support Programs

Cell therapies often require significant financial investment. Companies should prepare payment models before commercialisation begins. Support programs can also help patients understand reimbursement options and improve access to treatment.

Early planning reduces administrative delays and creates a smoother treatment process for healthcare providers and patients.

Why the Right CDMO Partnership Matters

Commercial readiness depends on strong coordination across multiple disciplines. Manufacturing, logistics, regulatory affairs, quality assurance, and commercial planning all influence product success.

Working with a trusted cell and gene therapy CDMO allows developers to focus on advancing innovative therapies while experienced specialists manage manufacturing complexity. Providers offering end-to-end CDMO services support companies throughout development, process optimisation, regulatory preparation, technology transfer, and commercial manufacturing. This integrated approach reduces operational challenges and helps maintain consistent quality from early development through commercial supply.

As demand for advanced therapies continues to grow, reliable cell therapy manufacturing services will remain an essential part of successful commercialisation strategies.

Conclusion

Commercialising a cell therapy requires careful planning long before the first commercial batch leaves the manufacturing facility. Every stage matters, from secure patient tracking and cryogenic logistics to automated production, regulatory compliance, and market access planning. Organisations that prepare these systems early place themselves in a stronger position to deliver safe, high-quality therapies while supporting long-term commercial growth.

Xellera Therapeutics provides advanced cell and gene therapy CDMO expertise, comprehensive end-to-end CDMO services, and reliable cell therapy manufacturing services to help developers move confidently from development to commercialisation. Connect with their team to build a scalable manufacturing strategy that supports your therapy at every stage of its lifecycle.